Chemoenzymatic synthesis of macrocyclic peptides and polyketides via thioesterase-catalyzed macrocyclization

• Senze Qiao,
• Zhongyu Cheng and
• Fuzhuo Li

Beilstein J. Org. Chem. 2024, 20, 721–733, doi:10.3762/bjoc.20.66

• macrolactones. Using engineered variants of S. venezuelae ATCC 15439 designated strains DHS200141 [71] and YJ11242 [72], 24 and 25 were transformed to the corresponding macrolides through whole cell biotransformation to append ᴅ-desosamine and perform C–H oxidation(s) by the PikC monooxygenase (Scheme 6b). In

Designed whole-cell-catalysis-assisted synthesis of 9,11-secosterols

• Marek Kõllo,
• Marje Kasari,
• Villu Kasari,
• Tõnis Pehk,
• Ivar Järving,
• Margus Lopp,
• Arvi Jõers and
• Tõnis Kanger

Beilstein J. Org. Chem. 2021, 17, 581–588, doi:10.3762/bjoc.17.52

• have presented the results of the synthesis of the 9,11-secosteroid carbon skeleton by using the designed whole-cell biotransformation of natural steroids with a genetically engineered biocatalyst. The enzymatic oxidation of cortisol derivatives is completely stereo- and regioselective, affording only

Engineering Pichia pastoris for improved NADH regeneration: A novel chassis strain for whole-cell catalysis

• Martina Geier,
• Christoph Brandner,
• Gernot A. Strohmeier,
• Mélanie Hall,
• Franz S. Hartner and
• Anton Glieder

Beilstein J. Org. Chem. 2015, 11, 1741–1748, doi:10.3762/bjoc.11.190

• utilization pathway; whole-cell biotransformation; Introduction Bioreductions represent a sustainable strategy to obtain enantiopure molecules which serve as chiral building blocks for fine chemicals and drugs [1][2]. Such reactions are catalyzed by oxidoreductases, which mainly depend on nicotinamide

• in 50 mL of buffered minimal medium before the conversions were started by the addition of substrate. During the first two hours of the whole-cell biotransformation, the conversions obtained with each of the strains were in the same order of magnitude (see Figure 4B). After longer reaction times

Chimeric self-sufficient P450cam-RhFRed biocatalysts with broad substrate scope

• Aélig Robin,
• Valentin Köhler,
• Alison Jones,
• Afruja Ali,
• Paul P. Kelly,
• Elaine O'Reilly,
• Nicholas J. Turner and
• Sabine L. Flitsch

Beilstein J. Org. Chem. 2011, 7, 1494–1498, doi:10.3762/bjoc.7.173

• mutation into our P450cam-RhFRed fused system made the whole cell biotransformation of diphenylmethane as a substrate possible (4 mL reaction in a 15 mL Falcon tube) with a GC–MS yield of 58% of 4-hydroxydiphenylmethane after 48 h (Scheme 1). In order to improve screening throughput, we investigated the

• whole cell biotransformation of diphenylmethane with P450cam(Y96A)-RhFRed in multiwell plates (24, 48 and 96) with different reaction volumes (0.5 mL, 1 mL and 2 mL). The biotransformation carried out in a 48-well plate with a reaction volume of 1 mL was found to give a similar conversion to the 4 mL

• attractive for the further discovery and development of new oxidation activity. Oxidation reactions with P450cam-RhFRed mutants. Whole cell biotransformation of diphenylmethane to 4-hydroxydiphenylmethane with P450cam(Y96A)-RhFRed. Conversion (% relative peak-area by GC–MS of extracted reaction mixtures